The St. Gallen International Consensus Session 2021 was held virtually in March, focused on the optimal treatment of women with early breast cancer. Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, shares the discussions that took place regarding the neoadjuvant and adjuvant treatment of patients with HER2-postive (HER2+) early breast cancer. The meeting established a broad consensus that a neoadjuvant approach was optimal in this setting. Some disagreement remained on the best chemotherapy backbone to use with neoadjuvant trastuzumab-pertuzumab dual blockade for HER2+ cancer, with different opinions on the necessity of anthracyclines. The optimal adjuvant regimen for node-positive and node-negative disease was also discussed, as well as the role of neratinib. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
